Pontifax

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, founded in 2015. The company focuses on developing therapeutic drugs aimed at enhancing the effectiveness of anti-cancer therapies. Its lead product, LUT014, is a proprietary small molecule B-Raf inhibitor designed to facilitate the administration of epidermal growth factor receptor (EGFR) inhibitors. This innovative approach helps mitigate the common cutaneous side effects associated with EGFR treatments, thereby improving the overall quality of life for patients undergoing cancer therapy.

Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

LB Pharmaceuticals Inc is a New York-based life sciences company focused on discovering and developing drugs for central nervous system disorders, particularly schizophrenia. Established in 2015, the company aims to commercialize novel and improved versions of existing CNS treatments that have not been developed or marketed in the United States. Its primary asset, LB-102 (n-Methyl amisulpride), is a patented reformulation of amisulpride, a drug recognized for its effectiveness in treating schizophrenia. By employing a pro-drug approach, LB Pharmaceuticals modifies the chemical structure of amisulpride to enhance its efficacy and safety, thereby offering improved treatment options for patients who do not respond well to current medications. The company is dedicated to generating innovative intellectual property and advancing its research-focused agenda in the pharmaceutical landscape.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Graviton Bioscience is a clinical-stage drug discovery and development firm focused on creating and developing therapies for the treatment of CNS, autoimmune, fibrotic, and other significant disorders in which ROCK2 plays a critical role in pathology.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

ARMGO Pharma, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutics aimed at treating debilitating cardiac, skeletal muscular, and neurological disorders. The company's primary product, Rycals, functions as calcium release channel stabilizers that target the ryanodine receptor/calcium release channel found on the sarcoplasmic/endoplasmic reticulum of cells. This innovative approach addresses conditions such as chronic heart failure, cardiac arrhythmias, muscle disorders, cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. Founded in 2004, ARMGO Pharma is headquartered in Tarrytown, New York, with an additional office in New York City.

Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients suffering from neurodegenerative diseases. The company leverages a technology platform that incorporates human genetics and patient-derived neuronal cells to identify and validate new disease pathways linked to lysosomal dysfunction and the inappropriate activation of the innate immune system. Vanqua Bio focuses on creating small-molecule activators of glucocerebrosidase and advancing programs that target the innate immune system, with the aim of addressing the progression of various neurological disorders. Through its efforts, the company seeks to provide healthcare professionals with transformative treatment options for patients facing these challenging conditions.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients by discovering, developing, and commercializing innovative targeted therapies. The company's primary focus is on addressing drug resistance mutations in key driver oncogenes, which are mutated genes that contribute to the progression of cancer. By leveraging advanced technologies, Theseus Pharmaceuticals aims to create transformative treatments that can overcome challenges associated with existing therapies, thereby improving patient outcomes in oncology.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, established in 2015. The company focuses on developing innovative adeno-associated viral (AAV) vector technologies and therapeutics aimed at treating rare diseases. Utilizing a proprietary platform that combines structural insights with accelerated evolution, StrideBio creates novel AAV capsids designed to evade neutralizing antibodies. This approach allows for enhanced gene addition, gene silencing, and gene editing capabilities, addressing the limitations of first-generation gene therapies. By engineering unique and differentiated vectors, StrideBio aims to improve treatment outcomes for patients facing devastating conditions.

EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Based in Newton, Massachusetts, Abcuro creates therapeutic antibodies targeting novel mechanisms related to these diseases. The company utilizes advanced bioinformatics to analyze transcription data from human diseases, which aids in the identification of new therapeutic targets. Through ex-vivo validation in diseased tissues, Abcuro seeks to uncover innovative methods to modulate key components of the immune system. Established in 2015, Abcuro aims to enhance treatment strategies in the healthcare industry by offering effective solutions for complex immunological conditions.

Allena Pharmaceuticals is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, that specializes in developing and commercializing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. The company's primary focus is on conditions that involve the excessive accumulation of metabolites such as oxalate and urate, which can lead to complications like kidney stones and chronic kidney disease. Allena's lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a disorder linked to significantly high urinary oxalate levels. Additionally, the company is developing ALLN-346, a novel enzyme designed to address hyperuricemia in patients with moderate to severe chronic kidney diseases. Allena Pharmaceuticals aims to provide innovative treatments that address unmet medical needs in these patient populations.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Neogene Therapeutics, Inc. is a biotechnology company based in New York, founded in 2018, that focuses on developing T cell therapies for cancer treatment. The company specializes in creating personalized engineered T cells that target neo-antigens, which are mutated proteins present in cancer cells due to DNA mutations. By leveraging advanced technologies, Neogene isolates T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies routinely collected from patients. This process utilizes high-sensitivity DNA sequencing and genetic screening to identify TCRs that can effectively recognize and attack cancer cells. Neogene's innovative approach aims to enhance the precision and efficacy of cancer therapies, offering improved treatment options for patients facing a broad spectrum of cancers.

Saniona is a pharmaceutical company dedicated to researching and developing innovative treatments for various diseases, including those affecting the central nervous system, autoimmune disorders, metabolic conditions, and pain management. The company specializes in the development of highly selective ion channel modulators, employing a technology platform that targets GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. Its most advanced product candidate, Tesomet, is currently in mid-stage clinical trials for rare eating disorders. Additionally, Saniona is advancing two other product candidates: SAN711, which has successfully completed a Phase 1 clinical trial for neuropathic pain conditions, and SAN903, which is preparing to enter Phase 1 trials for inflammatory and fibrotic disorders. The company is committed to leveraging its expertise in ion channel modulation to create effective new medicines.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

ProQR Therapeutics N.V. is a biopharmaceutical company based in Leiden, the Netherlands, focused on the discovery and development of RNA-based therapeutics for genetic disorders. The company is advancing several product candidates, including sepofarsen, which is in phase II/III clinical trials for Leber's congenital amaurosis 10, and QR-421a, currently in phase 1/2 trials for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in phase 1/2 trials for autosomal dominant retinitis pigmentosa, while QR-504a has commenced its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR has established collaborations with leading medical and research institutions, including General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is dedicated to developing innovative treatments for patients with severe genetic rare diseases.

Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation. Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON. Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.

Dynacure is a clinical-stage drug development company dedicated to enhancing the lives of patients with rare and orphan diseases. The company is advancing its lead product, DYN101, an investigational antisense medicine aimed at modulating the expression of dynamin 2 to treat Centronuclear Myopathies, in collaboration with Ionis Pharmaceuticals. In addition to DYN101, Dynacure is developing a complementary research portfolio that targets various other orphan disorders, including a program focused on hereditary spastic paraplegias linked to specific genetic mutations. Through its innovative approach and expertise in rare disease drug development, Dynacure seeks to address significant unmet medical needs in this underserved patient population.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment, specifically through neoantigen-specific adoptive T-cell therapies aimed at solid tumors. The company utilizes bioinformatics to analyze the DNA and RNA of patients' tumors and normal tissues, identifying candidate neoantigen peptides that can stimulate targeted antitumor T-cell responses. By recognizing unique neo-epitopes associated with individual cancers, PACT Pharma enables the engineering of autologous T cells designed to specifically target and eliminate tumor cells expressing these neoantigens. Founded in 2016 and based in South San Francisco, California, PACT Pharma is dedicated to advancing innovative treatment options for patients with cancer.

Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.

Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

Raziel Health is a pharmaceutical company based in Rehovot, Israel, focused on developing innovative treatments for obesity and related fat disorders. The company's primary product, RZL-012, is a synthetic small molecule designed for injection into subcutaneous fat, where it induces fat cell death at the injection site, leading to a significant and long-lasting reduction in fat tissue. Raziel Health is actively conducting clinical trials to explore the efficacy of RZL-012 for various fat-related conditions, including Dercum's disease, as well as for aesthetic purposes. In addition to its pharmaceutical endeavors, Raziel Health aims to enhance healthcare accessibility by offering integrated technologies that promote timely clinical intervention and support individual patient wellness and disease management from the comfort of their homes.

Adicet Bio is a clinical-stage biotechnology company focused on the design and development of allogeneic gamma delta T cell therapies aimed at treating cancer and other diseases. The company is advancing a pipeline of engineered gamma delta T cells, which are enhanced with chimeric antigen receptors and T cell receptor-like antibodies to improve tumor targeting and bolster the immune response. Its lead product candidate, ADI-001, is a first-in-class therapy that targets CD20 and is being developed for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Additionally, Adicet's pipeline includes ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential applications for other solid tumors and hematological malignancies.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

89bio, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, dedicated to developing therapies for liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) designed for the treatment of nonalcoholic steatohepatitis (NASH). This therapy is engineered to address key liver pathologies, including steatosis and fibrosis, as well as underlying metabolic dysregulation associated with NASH. Additionally, 89bio is expanding the potential applications of BIO89-100 to include the treatment of severe hypertriglyceridemia. Founded in 2018, 89bio aims to advance its innovative therapies through clinical development to meet significant unmet medical needs.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.

ABAC Therapeutics S.A., based in Barcelona, Spain, specializes in the development of precision antimicrobial agents aimed at treating multidrug-resistant (MDR) Gram-negative infections. Established in 2014, the company utilizes its innovative PasNas drug discovery platform to identify pathogen-specific antibacterial properties of various molecules. This platform not only focuses on potent antibacterial activity but also emphasizes the importance of favorable pharmacokinetics and toxicological profiles to enhance the likelihood of success in clinical development. ABAC Therapeutics seeks to provide first-in-class therapeutic alternatives for patients suffering from infections caused by antibiotic-resistant bacterial pathogens, particularly targeting the significant challenge posed by the major MDR Gram-negative bacteria. As of November 2019, the company operates as a subsidiary of Tibidabo Ventures.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

LogicBio Therapeutics is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly those affecting pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology, LogicBio aims to integrate corrective genes into patients' genomes, offering potential therapeutic benefits. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a severe condition that manifests at birth. Additionally, LogicBio is advancing other candidates, including LB-301, which is being developed in collaboration with Takeda Pharmaceutical Company for Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors. Founded in 2014 and based in Lexington, Massachusetts, LogicBio is focused on delivering safe and effective genetic medicine to patients suffering from previously untreatable genetic and infectious diseases.

Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

Tisbury Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of therapies for the treatment of primary open angle glaucoma. Founded in 2017 and based in Beverly, Massachusetts, the company focuses on its clinical candidate, R-801, which aims to enhance fluid flow through the trabecular meshwork by utilizing redox catalysis and K+-ATP channel activation. This innovative approach targets the drainage openings in the eye, significantly reducing intraocular pressure in patients suffering from glaucoma.

TargEDys is a company based in Rouen, France, that specializes in developing innovative treatments for eating disorders such as hyperphagia and anorexia. Established in 2011, TargEDys focuses on harnessing hormone mimetic proteins associated with the gut microbiota to regulate appetite. Their approach involves utilizing natural bacterial proteins found in the gut microbiome to modulate eating behavior, helping to control appetite in overweight individuals and restore normal eating patterns in elderly or cachexic patients. Through its research and development efforts, TargEDys aims to provide effective solutions for those struggling with metabolic diseases related to appetite regulation.

EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.

ARTSaVIT is a biopharmaceuticals company developing a cancer drug.

Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability. They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel, specializing in the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product candidates include EB612, an oral formulation of parathyroid hormone currently in Phase II clinical trials for hypoparathyroidism, and EB613, which is also in Phase II trials for osteoporosis and under development for non-union fractures. Entera Bio employs proprietary delivery technology that protects large molecules and peptides in the gastrointestinal tract, making oral drug administration straightforward and user-friendly. The company has established a research collaboration and license agreement with Amgen Inc. to discover clinical candidates targeting inflammatory diseases and other serious conditions. Founded in 2009, Entera Bio is supported by a management team with over 50 years of combined experience in drug development.

TargEDys is a company based in Rouen, France, that specializes in developing innovative treatments for eating disorders such as hyperphagia and anorexia. Established in 2011, TargEDys focuses on harnessing hormone mimetic proteins associated with the gut microbiota to regulate appetite. Their approach involves utilizing natural bacterial proteins found in the gut microbiome to modulate eating behavior, helping to control appetite in overweight individuals and restore normal eating patterns in elderly or cachexic patients. Through its research and development efforts, TargEDys aims to provide effective solutions for those struggling with metabolic diseases related to appetite regulation.

Sweetch is a behavioral science company that utilizes artificial intelligence and emotional intelligence to provide digital therapeutic solutions aimed at improving clinical outcomes for individuals with chronic conditions. The company's hyper-personalized engagement platform offers tailored recommendations that consider the appropriate timing, tone, and real-world context for each patient's health journey. This approach enables pharmaceutical companies, medical device manufacturers, payers, and healthcare providers to foster continuous relationships and effectively engage with patients at scale, ultimately supporting individuals in achieving their health goals.

Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.

OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions. In addition to our flagship product, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.

Adicet Bio is a clinical-stage biotechnology company focused on the design and development of allogeneic gamma delta T cell therapies aimed at treating cancer and other diseases. The company is advancing a pipeline of engineered gamma delta T cells, which are enhanced with chimeric antigen receptors and T cell receptor-like antibodies to improve tumor targeting and bolster the immune response. Its lead product candidate, ADI-001, is a first-in-class therapy that targets CD20 and is being developed for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Additionally, Adicet's pipeline includes ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential applications for other solid tumors and hematological malignancies.

Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com

EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.

OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions. In addition to our flagship product, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Isfiya, Israel, specializing in the development of a capsule-based system for colorectal cancer screening. The company's flagship product, C-Scan, employs low-dose X-rays to screen for polyps, masses, and colorectal cancers without the need for bowel preparation or invasive procedures. The C-Scan system comprises three components: the C-Scan Cap, an ingestible capsule that captures and transmits structural data; the C-Scan Track, a biocompatible device worn on the patient's back for tracking and data recording; and C-Scan View, software for processing and visualizing the collected clinical data. This innovative approach allows for the detection of clinically significant polyps with accuracy comparable to traditional colonoscopy while eliminating the need for retrieval of the capsule post-examination. Check-Cap aims to market its products in the United States, Europe, Israel, and Japan.

Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.

HeadSense Medical Ltd. is an early-stage company based in Netanya, Israel, focused on developing non-invasive diagnostic devices for brain health. Established in 2011, the company has created a validated and CE Mark approved intracranial pressure (ICP) monitor that is applicable in various medical fields, including neurosurgery, neurology, emergency medicine, and critical care. The device allows healthcare professionals to diagnose and monitor critical clinical parameters without the need for invasive procedures. In addition to its ICP monitor, HeadSense is actively working on expanding its product offerings to include diagnostic tools for cerebral vasospasm, concussion, and the quantification of traumatic brain injury severity, among others. The company operates in both the U.S. and Israel, aiming to enhance patient outcomes through innovative monitoring solutions.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Lifeward is a medical device company based in Marlborough, Massachusetts, that focuses on developing, manufacturing, and marketing advanced walking systems for individuals with lower limb disabilities. Its primary products are the ReWalk Rehabilitation System and the ReWalk Personal System. The ReWalk Rehabilitation System is designed for use in rehabilitation centers, enabling users to walk, stand, sit, and navigate stairs. In contrast, the ReWalk Personal System is tailored for everyday use across various environments, including homes and workplaces, and allows users to perform activities such as sitting, standing, and stair climbing. Lifeward's innovative robotic technologies aim to improve the quality of life for individuals with spinal cord injuries and other mobility impairments, offering functional and health benefits in both clinical settings and the broader community. The company operates primarily in the United States and Europe, with additional sales in Asia, the Middle East, and South America.

UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, focused on developing innovative therapies for specialty cancers and urologic diseases. The company is dedicated to transforming the standard of care in uro-oncology through its diverse pipeline of product candidates. Its lead products, including UGN-101 and UGN-102, aim to ablate tumors non-surgically and address various forms of non-muscle invasive urothelial cancer, such as low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. UroGen is also advancing UGN-201, an immunotherapy candidate targeting high-grade non-muscle invasive bladder cancer. Furthermore, the company's proprietary RTGel technology enhances drug delivery by enabling sustained release, improving therapeutic efficacy. UroGen has established licensing agreements with Allergan Pharmaceuticals for the development of RTGel-based products and with Agenus Inc. to commercialize treatments for urinary tract cancers. Founded in 2004, UroGen Pharma continues to innovate in the field of urology and oncology.

OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions. In addition to our flagship product, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.

cCAM Biotherapeutics Ltd. is a clinical-stage company focused on the discovery and development of novel immunotherapies for cancer treatment. Founded in 2010 and based in Misgav, Israel, the company is advancing its lead candidate, CM-10, an immunomodulatory antibody designed to counteract the immunosuppressive effects of CEACAM1, a protein utilized by cancer cells. By inhibiting this protein, CM-10 aims to stimulate a cancer-specific immune response, targeting various malignancies such as melanoma, non-small-cell lung cancer, bladder cancer, gastric cancer, colorectal cancer, and ovarian cancer. cCAM Biotherapeutics is dedicated to developing innovative therapeutic solutions to improve outcomes for cancer patients.

MacroCure is a biotechnology company focused on the development and commercialization of advanced cell therapy products. The company's first focus of interest is in the arena of wound care. The technology employs activated white blood cells obtained from young adults healthy donor blood. The activated cells provide the natural environment for wound healing, and ensure that necessary cell activities and factor secretions are maintained as required for wound healing. This novel concept is the first of its kind in the field of wound therapy.

Stimatix GI is an early-stage startup founded in June 2009, operating under the Misgav Venture Accelerator and jointly funded by the Office of the Chief Scientist. The company has developed a product line known as the Artificial Ostomy Sphincter (AOS), which includes the AOS-1000 and AOS-C2000. These innovative colostomy devices provide patients with the ability to control bowel evacuation, significantly improving their quality of life. The AOS products are designed to seal the stoma, eliminating the issues associated with traditional adhesive bags, and offer a low-profile, aesthetically pleasing solution. By providing users with the autonomy to decide when and where to evacuate, these devices simplify the evacuation process, making it quicker and cleaner. Additionally, the hermetic seal of the AOS products helps prevent skin irritation and folliculitis, addressing common discomforts associated with ostomy care.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, focused on developing innovative diagnostic and therapeutic drugs. Established in 1996, Aposense specializes in utilizing its patented platform technology to target apoptosis, or programmed cell death, which enables real-time imaging of disease activity and the development of targeted therapies. The company innovates in gene therapy by creating transport molecules that facilitate the introduction of genetic material, particularly small interfering RNA (siRNA), through biological membranes. Aposense is also known for its molecular nano-motors, which are designed to harness electrical properties of membranes for drug delivery, including its development of ATT-11T, a conjugate aimed at treating solid tumors.

Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications in pathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.